SCHEMBL10274656

SCHEMBL10274656

C1CCCN(c2nnn[nH]2)CC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
CYP2C19 P33261 1/20 0.37
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35
HPGD P15428 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
USP2 O75604 2/20 0.34
TDP1 Q9NUW8 2/20 0.34
ALDH1A1 P00352 3/20 0.32
GAA P10253 2/20 0.32
HSD17B10 Q99714 2/20 0.32
MAPK1 P28482 2/20 0.32
PIM1 P11309 1/20 0.32
TSHR P16473 2/20 0.32
GFER P55789 2/20 0.32
NPC1 O15118 1/20 0.32
TP53 P04637 1/20 0.32
NFKB1 P19838 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5394656 1.00 CYP1A2 (0.37) CYP1A2MEN1KMT2ACYP2C19BCHE
SCHEMBL943173 1.00 CYP1A2 (0.37) CYP1A2MEN1KMT2ACYP2C19BCHE
SCHEMBL31759376 1.00 CYP1A2 (0.37) CYP1A2MEN1KMT2ACYP2C19BCHE
Hydrochloric Acid SCHEMBL28360015 0.98 CYP1A2 (0.36) CYP1A2MEN1KMT2ACYP2C19BCHE
SCHEMBL628830 0.98 MEN1 (0.34) CYP1A2MEN1KMT2ACYP2C19BCHE
SCHEMBL10493476 0.93
SCHEMBL4174000 0.78 PIM1 (0.39) MEN1KMT2ASMN1; SMN2PIM1NPC1
SCHEMBL31759418 0.78 TRPC3 (0.38) MEN1KMT2AHPGDSMN1; SMN2USP2
SCHEMBL31759472 0.78 TRPC3 (0.38) MEN1KMT2AHPGDSMN1; SMN2USP2
SCHEMBL31759401 0.78 TRPC3 (0.38) MEN1KMT2AHPGDSMN1; SMN2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680335-A1 UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF Ventus Therapeutics U.S., Inc. (US) 2026-01-21 EP disclosed
US-20260007684-A1 AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U S INC (US) 2026-01-08 US disclosed
US-20260008768-A1 UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U S INC (US) 2026-01-08 US disclosed
WO-2024196786-A1 UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2024-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260008768-A1 UREA DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF NOD1, NLRP3, NOD2 CYP1A2 2180/4885MEN1 4308/4885KMT2A 4683/4885
US-20260007684-A1 AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF NOD1, NLRP3, NOD2 CYP1A2 1650/4885MEN1 4331/4885KMT2A 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.